Efficacy and Cardiovascular Safety of Topical Timolol, Brimonidine & Latanoprost in Newly Diagnosed Patients of Open Angle Glaucoma.

ABSTRACT

The present study was conducted in chronic open angle glaucoma patients to evaluate their efficacy in reducing IOP and their cardiovascular safety. 48 newly diagnosed patients of glaucoma completed the trial. Patients were divided into three groups and received medications in form of topical instillations. Group I (Timolol 0.5% twice a day), Group II (Brimonidine Tatrate 0.2% twice a day) & Group III (Latanoprost 0.005% once a day) for 12 weeks. All the three medications, significantly decreased IOP (P<0.05), however, Latanoprost caused maximum decrease in IOP, followed by Brimonidine and Timolol. Visual Acquity was not affected by any of the medication. Pulse Rate and PR Interval were decreased in Timolol group significantly (P < 0.001) while Brimonidine and Latanoprost did not alter Pulse Rate. Blood Pressure was not affected by either of medication except Brimonidine which caused reduction in systolic Blood Pressure at 12 weeks. The results of present study demonstrates superiority of Latanoprost over Timolol and Brimonidine as it lacked effect on Pulse Rate, Blood Pressure and HR, besides being more efficacious.